Drug Target ReviewGene therapy may lower risk for heart diseaseDrug Target ReviewResearchers have tested whether a single injection of the gene, LeXis could slow down the development of heart disease, scientists successfully used the gene that suppress… Continue reading
ETHealthworld.com |
ICMR’s stem cell research guidelines soon to be released
ETHealthworld.com New Delhi: Indian Council of Medical Research (ICMR) will soon release the final document on guidelines for stem cell research, the draft of which was available on the ICMR and the DBT (Department of Biotechnology) websites for public reviews till July … |
|
Gilead buys into CAR–T with $11.9bn deal for Kite
PharmaTimes Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline. … involves drawing T cells from a patient’s blood and … So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches EyeNasdaq |
CNN |
Price tag fears cast shadow over ‘revolutionary’ leukemia drug – CNN
CNN When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like “breakthrough.” But when they think about how much the … The Promising New Cancer Treatment Behind Gilead’s $11 Billion …Fox Business |
Devon Live |
Devon scientist plans to develop Borg technology
Devon Live A Devon scientist inspired by Star Trek enemies The Borg plans to create living nanotechnology which will be integrated into ‘biological machines’. Dr Raymond Sparrow says synthetic biology could be the basis of a whole new industry and he has written … |